<DOC>
	<DOC>NCT00296517</DOC>
	<brief_summary>This study is designed to evaluate the efficacy and safety in depressive patients who did not respond sufficiently to selective serotonin re-uptake inhibitors (SSRI).</brief_summary>
	<brief_title>Study In Patients With Depression Not Responding to Selective Serotonin Re-uptake Inhibitors</brief_title>
	<detailed_description />
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depressive Disorder, Major</mesh_term>
	<mesh_term>Serotonin</mesh_term>
	<mesh_term>Bupropion</mesh_term>
	<mesh_term>Serotonin Uptake Inhibitors</mesh_term>
	<criteria>Inclusion criteria: [At the start of the pretreatment phase] Target disease: Patients diagnosed as having the following primary disease on the basis of DSMIVTR criteria. Major Depressive Disorder, Single Episode (296.2x) (excluding with psychotic features) Major Depressive Disorder, Recurrent (296.3x) (excluding with psychotic features) HAMD (17 items) total score is &gt;=16. Patients who have been treated with marketed paroxetine (Paxil®) at 20mg/day to 40mg/day for 4 weeks and more at the start of the pretreatment phase. Age: &gt;=18 years old (at the time of informed consent) , &lt;65 years old (at the start of treatment phase ) Gender: Male or female. Inpatients or outpatients: Either Informed consent: The subject himself/herself must give written informed consent. However, if the subject is under 20 at the time of giving consent, both the subject himself/herself and his/her legally acceptable representative must give written informed consent. [At the end of the pretreatment phase] 1. HAMD (17 items) total score is ≥14. 2. Percentage of change from the start of the pretreatment phase in the HAMD (17 items) total score is &lt;50% [At the start of the treatment phase] 1. HAMD (17 items) total score is ≥14. 2. Percentage of change from the start of the pretreatment phase in the HAMD (17 items) total score is &lt;50% [At the start of the pretreatment phase] Patients with a complication of glaucoma Patients concomitantly using a drug increasing the risk of bleeding and patients with bleeding tendency or predisposition to bleeding Patients with predisposition to seizure (who currently have or have a past history of seizure, febrile convulsive seizure in infancy, cerebral tumour, cerebrovascular disorder or head injury, who have a family history of idiopathic seizure, patients with diabetes who have been treated with oral hypoglycaemics or insulin, or who use drugs lowering the threshold of seizure). Patients who currently have or have a past history of the following disorders: Anorexia nervosa (DSMIVTR 307.1) Bulimia nervosa (DSMIVTR 307.51) Patients with a history of manic episode Patients with a past or current DSM IVTR diagnosis of schizophrenia or other psychotic disorder Patients with a current DSMIVTR Axis II diagnosis (e.g., antisocial or borderline personality disorder) Patients starting psychotherapy (except for supportive psychotherapy not aimed at therapeutic efficacy and unlikely to affect efficacy evaluation) and formal cognitive behaviour therapy within 5 weeks prior to the start of the pretreatment phase Patients with a diagnosis of substance abuse (alcohol or drug) by the DSMIVTR criteria or with a diagnosis of substance dependence within 1 year prior to the start of the pretreatment phase Patients who have received electroconvulsive therapy within 17 weeks prior to the start of the pretreatment phase Patients who have taken MAO inhibitors (selegiline hydrochloride) within 2 weeks prior to the start of the pretreatment phase Patients who have taken another investigational drug within 12 weeks prior to the start of the pretreatment phase Female patients who are pregnant, possibly pregnant or are nursing, and those who want to become pregnant before 30 days after the last dose of the investigational product Patients who have attempted suicide within 17 weeks prior to the start of the pretreatment phase, or patients for whom the score of suiciderelated item No. 3 of HAMD is &gt;=3, or patients in whom the risk of suicide is judged to be high by the investigator (subinvestigator) Patients in whom the risk of homicide is judged to be high by the investigator (subinvestigator) Patients with a history of hypersensitivity to 323U66 and/or paroxetine Patients with serious cerebral disease Patients who have ECG or clinical evidence of any cardiac condition that the investigator (subinvestigator) feels may predispose the subject to ischemia or arrhythmia Patients with serious physical symptoms (i.e. cardiac/hepatic/renal disorder, hematopoietic disorder) The index of seriousness is Grade 3 of "Criteria for classification of seriousness of adverse drug reactions to pharmaceutical products, etc." (PAB/PSD No.80 in 1992). Patients with a history or complication of cancer or malignant tumour. Patients whose major depressive disorder is due to direct physiological effects of a general medical condition (for example, hypothyroidism, Parkinson's disease, chronic pain) Patients with systolic blood pressure of &gt;=160 mmHg or diastolic blood pressure of &gt;=100 mmHg Patients who are inappropriate for participating in the study in the judgement of the investigator (subinvestigator) [At the start of the treatment phase] 1. Patients whose compliance of paroxetine during the pretreatment phase is less than 70%. 2. Patients who have ECG or clinical evidence of any cardiac condition that the investigator (subinvestigator) feels may predispose the subject to ischemia or arrhythmia 3. Patients with systolic blood pressure of &gt;=160 mmHg or diastolic blood pressure of &gt;=100 mmHg</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2009</verification_date>
	<keyword>bupropion hydrochloride</keyword>
	<keyword>SSRI</keyword>
	<keyword>non-responder</keyword>
	<keyword>depression</keyword>
	<keyword>placebo-controlled</keyword>
	<keyword>double-blind</keyword>
	<keyword>comparative study</keyword>
</DOC>